MorphoSys AG — Board/Management Information 1999

Jul 29, 1999

News Details

Ad-hoc | 29 July 1999 07:40

Ad hoc-Service: MorphoSys AG Board_E

Ad-hoc Mitteilung übermittelt durch die DGAP. Für den Inhalt der Mitteilung ist allein der Emittent verantwortlich. —————————————————————————— Press Release Munich, Germany, 29 July 1999 MORPHOSYS ANNOUNCES CHANGES TO BOARD OF DIRECTORS AND APPOINTS NEW CHAIRMAN MorphoSys AG (Neuer Markt: MOR), the Munich-based combinatorial biology company, announced the appointment of Dr Gerald Moeller as Non-Executive Chairman of its Board. Dr Geoffrey Vernon, formerly an investment manager at the Rothschilds Bioscience Unit and currently Managing Director, Ziggus Holding Ltd., and Robert Schneider, Executive Chairman of SCM Microsystems Inc., have been appointed as Non-Executive Directors. The appointments take effect immediately. In accordance with their respective contracts, Dr. Goeran Ando will retire as Chairman and Alex Korda will step down from his position as Non-Executive Director, with immediate effect. Dr Moeller’s career includes 24 years at Boehringer Mannheim GmbH where he held a number of senior management positions, including 3 years as Chief Executive Officer of the worldwide operation Boehringer Mannheim Group. Following the acquisition of Boehringer Mannheim by Roche, he became a member of the Roche Group’s Central Management headquartered in Basle. Currently Dr Moeller heads the department of Intelligent Health Care at ESG Limited. He holds a PhD in Chemistry. “I am very much looking forward to being involved with one of Europe’s leading biotechnology companies”, commented Dr Moeller. “MorphoSys has established a powerful portfolio of drug and target discovery technologies, and I expect to be able to help the company further commercialise its capabilities.” Dr Simon Moroney, Chief Executive Officer of MorphoSys thanked the departing board members. “I am very grateful for the invaluable input from Alex Korda and Goeran Ando. Alex Korda has supported the company since its early days and his enthusiasm has greatly contributed to the success of MorphoSys. Now that the company is no longer a fledgling he will move on to concentrate on other business ventures.” He continued, “Dr Ando fulfilled his promise to the company of guiding it through a successful IPO, and leaves to spend more time on alternative pursuits. He was delighted to appoint such an experienced successor in Gerald Moeller.” MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterisation. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers world-wide for human antibody generation. The Company has partnered with pharmaceutical companies such as Pharmacia & Upjohn and Boehringer Mannheim, and currently has licensing and research collaborations with DuPont Pharmaceuticals (Wilmington, Delaware), LeukoSite (Cambridge, Mass), and Chiron Corporation (Emeryville, California). This year the Company signed a further co-operation with GPC AG (Martinsried/ Munich). In March 1999, MorphoSys AG became the first biopharmaceutical company to list on Germany’s Neuer Markt. For more information, please contact: Simon Moroney Chief Executive Officer MorphoSys AG Tel: +49 (0) 89 899 27 0 Fax: +49 (0) 89 899 27 222 Ende der Mitteilung